Essex Woodlands Management, Inc. Long-Term Concentrated

CIK: 0001542339 · Show all filings

Period: Q2 2019 (← Previous) (Next →)

Filing Date: Aug 14, 2019

Total Value ($000): $173,431 (100.0% shares, 0.0% debt)

Holdings (6)

— EYEPOINT PHARMACEUTICALS INC 39.6%

Value ($000) $68,731 Shares 41,909,219 Est. Cost $1.64 Unrealized —

AXGN AXOGEN INC 27.7%

Value ($000) $48,114 Shares 2,429,999 Est. Cost $4.01 Unrealized +434.1%

— REVANCE THERAPEUTICS INC 25.0%

Value ($000) $43,346 Shares 3,342,047 Est. Cost $31.50 Unrealized —

MNOV MEDICINOVA INC 6.5%

Value ($000) $11,271 Shares 1,170,370 Est. Cost $2.95 Unrealized +257.4%

— ENDOLOGIX INC 0.8%

Value ($000) $1,390 Shares 125,747 Est. Cost $11.05 Unrealized —

— CATALYST BIOSCIENCES INC 0.3%

Value ($000) $579 Shares 78,622 Est. Cost $7.36 Unrealized —

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
—	EYEPOINT PHARMACEUTICALS INC	41,909,219	$68,731	39.6%	$1.64	—	COM	30233G100
AXGN	AXOGEN INC	2,429,999	$48,114	27.7%	$4.01	+434.1%	COM	05463X106
—	REVANCE THERAPEUTICS INC	3,342,047	$43,346	25.0%	$31.50	—	COM	761330109
MNOV	MEDICINOVA INC	1,170,370	$11,271	6.5%	$2.95	+257.4%	COM NEW	58468P206
—	ENDOLOGIX INC	125,747	$1,390	0.8%	$11.05	—	COM NEW	29266S304
—	CATALYST BIOSCIENCES INC	78,622	$579	0.3%	$7.36	—	COM NEW	14888D208